Supplementary Figure S3 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma

Authors: Helen D. Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>. IL2 linearity, related to Figure 2. Each dose of AVB-001 administered resulted in a proportional, linear increase in serum IL2 levels. Data are presented as mean ± SEM.</p></jats:p>

Keywords

linearity related figure each dose

Supplementary Figure S3 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma

Abstract

Keywords

Related Articles

Supplementary Figure 9 from Targeting the NAD&lt;sup&gt;+&lt;/sup&gt; Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells

Supplementary Figure S3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade

Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Supplementary Table S6 from &lt;i&gt;Helicobacter pylori&lt;/i&gt; Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis

Data from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Supplementary Figure 9 from Targeting the NAD<sup>+</sup> Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells

Supplementary Table S6 from <i>Helicobacter pylori</i> Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis